Royalty Pharma (RPRX) Q3 FY2026 earnings: revenue $690 million, up 13.3% on the year
Royalty Pharma plc (RPRX) reported revenue of $690 million for Q3 FY2026, the quarter ended 30 September 2026, up 13.3% on the same quarter a year earlier. Net income was $145 million, down 49.1% on the year, and diluted earnings per share $0.32. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
| $ million | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Revenue | 690 | 674 | 609 | +2.4% | +13.3% | |
| Research and development | 63.2 | 97.9 | 50.5 | -35.5% | +25.1% | |
| Operating income | 411 | 133 | 427 | +208.6% | -3.8% | |
| Operating margin | 59.5% | 19.7% | 70.1% | |||
| Interest expense | 90.5 | 93.6 | 79.6 | -3.3% | +13.7% | |
| Pre-tax income | 267 | 81.5 | 440 | +227.2% | -39.4% | |
| Income tax | 0.0 | 0.0 | 0.0 | |||
| Effective tax rate | 0.0% | 0.0% | 0.0% | |||
| Net income | 145 | 17.9 | 284 | +709.0% | -49.1% | |
| Net margin | 21.0% | 2.7% | 46.6% | |||
| Diluted EPS | $0.32 | $0.04 | $0.67 | +700.0% | -52.2% |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.Cash flow
| $ million | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Operating cash flow | 686 | 728 | 703 | -5.8% | -2.4% | |
| Cash from investing | -286 | -230 | -958 | |||
| Cash from financing | -699 | -273 | 563 | |||
| Share-based compensation | 105 | 107 | 73.4 | -2.1% | +43.3% | |
| Buybacks | 86.3 | 44.6 | 146 | +93.4% | -41.1% | |
| Dividend per share | $0.23 | $0.23 | $0.22 | 0.0% | +6.8% | |
| Diluted shares, weighted | 557m | 557m | 560m | +0.0% | -0.5% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
| $ million | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | On the quarter | On the year | Last 8 quarters |
|---|---|---|---|---|---|---|
| Shareholders' equity | 9,795 | 9,786 | 9,621 | +0.1% | +1.8% | |
| Debt | 8,587 | 8,962 | 8,946 | -4.2% | -4.0% | |
| Other liabilities | 1,078 | 1,072 | 781 | +0.6% | +38.1% | |
| Total liabilities and equity | 19,461 | 19,820 | 19,347 | -1.8% | +0.6% | |
| Goodwill | 924 | 924 | 925 | 0.0% | -0.1% | |
| Investments | 381 | 397 | 319 | -4.0% | +19.6% | |
| Cash and equivalents | 514 | 812 | 939 | -36.7% | -45.3% | |
| Other assets | 17,643 | 17,687 | 17,165 | -0.3% | +2.8% | |
| Total assets | 19,461 | 19,820 | 19,347 | -1.8% | +0.6% |
Questions
What was Royalty Pharma's revenue in Q3 FY2026?
Royalty Pharma (RPRX) reported revenue of $690 million for Q3 FY2026, the quarter ended 30 September 2026, up 13.3% on the same quarter a year earlier.
How much did Royalty Pharma earn in Q3 FY2026?
Net income for Q3 FY2026 was $145 million, down 49.1% on the year, and diluted earnings per share $0.32.
When did Royalty Pharma report Q3 FY2026 results?
Royalty Pharma filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.
Quarterly results, the last 20 quarters
| Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 † | Q2 FY2025 † | Q3 FY2025 † | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 576 | 562 | 536 | 573 | 566 | 684 | 538 | 536 | 596 | 568 | 537 | 565 | 594 | 568 | 579 | 609 | 622 | 631 | 674 | 690 |
| R&D | 104 | 100 | 0.6 | 25.5 | 50.5 | 0.5 | 0.5 | 50.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 50.5 | 300 | 50.5 | 50.5 | 39.8 | 97.9 | 63.2 |
| Operating income | 153 | 220 | 378 | 192 | -483 | 479 | 249 | 151 | 613 | -73.8 | 270 | 735 | 362 | 534 | 210 | 427 | 388 | 563 | 133 | 411 |
| Operating margin | 27% | 39% | 70% | 34% | -85% | 70% | 46% | 28% | 103% | -13% | 50% | 130% | 61% | 94% | 36% | 70% | 62% | 89% | 20% | 60% |
| Interest expense | 47.0 | 47.1 | 47.0 | 47.0 | 47.0 | 47.0 | 46.9 | 46.0 | 47.3 | 44.2 | 49.0 | 66.5 | 65.8 | 65.3 | 68.7 | 79.6 | 94.2 | 93.7 | 93.6 | 90.5 |
| Pre-tax income | 53.7 | 128 | 492 | 220 | -610 | 509 | 351 | 122 | 718 | -4.3 | 194 | 806 | 334 | 434 | 92.6 | 440 | 356 | 468 | 81.5 | 267 |
| Tax rate | 0% | 0% | 0% | 0% | n/a | 0% | 0% | 0% | 0% | n/a | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net income | 7.9 | 51.8 | 305 | 143 | -456 | 341 | 228 | 72.1 | 494 | 4.8 | 102 | 544 | 208 | 239 | 32.2 | 284 | 214 | 295 | 17.9 | 145 |
| Net margin | 1% | 9% | 57% | 25% | -81% | 50% | 42% | 13% | 83% | 1% | 19% | 96% | 35% | 42% | 6% | 47% | 34% | 47% | 3% | 21% |
| Diluted EPS | n/a | $0.12 | $0.70 | $0.32 | n/a | $0.76 | $0.50 | $0.16 | $1.11 | $0.01 | $0.23 | $1.21 | $0.46 | $0.55 | $0.07 | $0.67 | $0.49 | $0.67 | $0.04 | $0.32 |
| Operating cash flow | 490 | 460 | 575 | 539 | 570 | 1,034 | 608 | 574 | 773 | 665 | 658 | 704 | 743 | 596 | 364 | 703 | 827 | 718 | 728 | 686 |
| Buybacks | n/a | n/a | n/a | 0.0 | n/a | n/a | n/a | 140 | n/a | 0.0 | 80.0 | 97.0 | 52.6 | 709 | 292 | 146 | 80.5 | 50.1 | 44.6 | 86.3 |
| Filing | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A blank figure marked on a quarter is one the filings do not give on their own: the quarters as filed do not add to the year the company filed, or the year and its quarters stand on different share counts. Each quarter's page says which. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.